Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

PURPOSE: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. METHODS: Patients had confirmed symptomatic WM, either previously untre...

Descripción completa

Detalles Bibliográficos
Autores principales: Buske, Christian, Tedeschi, Alessandra, Trotman, Judith, García-Sanz, Ramón, MacDonald, David, Leblond, Veronique, Mahe, Beatrice, Herbaux, Charles, Matous, Jeffrey V., Tam, Constantine S., Heffner, Leonard T., Varettoni, Marzia, Palomba, M. Lia, Shustik, Chaim, Kastritis, Efstathios, Treon, Steven P., Ping, Jerry, Hauns, Bernhard, Arango-Hisijara, Israel, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683240/
https://www.ncbi.nlm.nih.gov/pubmed/34606378
http://dx.doi.org/10.1200/JCO.21.00838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683240/
https://www.ncbi.nlm.nih.gov/pubmed/34606378
http://dx.doi.org/10.1200/JCO.21.00838

Ejemplares similares